Region Joenkoepings Laen
- Address
- lock Available on a paid plan
Retinopathy of Prematurity Research
The Department of Ophtalmology at Region Joenkoepings Laen is conducting a study that evaluates whether topical dexamethasone eye drops can lower the number of infants who require conventional treatment for retinopathy of prematurity.
- Preventative eye‑drop therapy for premature infants
- Reduction of invasive laser or cryotherapy procedures
- Monitoring safety and visual outcomes
The trial involves a multidisciplinary team of 29 investigators and aims to improve early‑intervention strategies for this vulnerable population.
Renal and Skin Cancer Trials
Researchers at the site are evaluating new immune‑targeted combination therapies for patients with advanced clear cell renal cancer and melanoma, focusing on improving survival outcomes.
- Comparison of novel combination regimens versus standard care
- Measurement of progression‑free survival
- Assessment of overall survival benefits
- Exploration of adjuvant strategies after surgery
With 29 investigators participating, the program seeks to bring more effective systemic options to patients with these high‑risk cancers.
Bladder Cancer Adjuvant Instillation Study
The clinic is running a comparative trial of gemcitabine versus mitomycin as adjuvant intravesical therapy for non‑muscle invasive bladder cancer at intermediate risk of recurrence.
- Direct comparison of two instillation agents
- Evaluation of recurrence‑free survival
- Focus on patients after transurethral tumor resection
- Safety and tolerability monitoring
This research supports the goal of reducing bladder cancer recurrence and improving quality of life for patients treated at the Jönköping facility.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 14 therapeutic areas and 15 of 89 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 82 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Vaestra Goetalandsregionen4active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Vaestra Goetalandsregionen6trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Joenkoepings Laen
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized Controlled Trial Comparing Dapagliflozin Propanediol and Metformin in Early Stage Type 2 Diabetes for Mortality and Vascular Complications | Uppsala University | Phase III | Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 89 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2019-06-07 | 2024-11-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.